Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML

Tyrosine kinase inhibitors (TKIs) are established drugs in the therapy of FLT3-ITD mutated acute myeloid leukemia (AML). However, acquired mutations, such as D835 in the tyrosine kinase domain (FLT3-ITD/D835), can induce resistance to TKIs. A cap analysis gene expression (CAGE) technology revealed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamatani, Kotoko, Ai, Tomohiko, Saito, Kaori, Suzuki, Koya, Hori, Atsushi, Kinjo, Sonoko, Ikeo, Kazuho, Ruvolo, Vivian, Zhang, Weiguo, Mak, Po Yee, Kaczkowski, Bogumil, Harada, Hironori, Katayama, Kazuhiro, Sugimoto, Yoshikazu, Myslinski, Jered, Hato, Takashi, Miida, Takashi, Konopleva, Marina, Hayashizaki, Yoshihide, Carter, Bing Z., Tabe, Yoko, Andreeff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818561/
https://www.ncbi.nlm.nih.gov/pubmed/35114569
http://dx.doi.org/10.1016/j.tranon.2022.101354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818561/
https://www.ncbi.nlm.nih.gov/pubmed/35114569
http://dx.doi.org/10.1016/j.tranon.2022.101354

Ejemplares similares